Loading
Loading
Research Overview
Truncated IGF-1 variant lacking N-terminal tripeptide; reduced IGFBP binding affinity in some tissues enables more immediate IGF-1R access and localised anabolic pathway activation (PI3K/Akt/mTOR, Ras/MAPK) with shorter systemic duration than IGF-1 LR3.
IGF-1 DES is a naturally-occurring truncated variant of IGF-1, missing its first three N-terminal amino acids. This structural difference reduces its binding affinity to IGF-binding proteins (IGFBPs) in some tissue contexts, which means the compound is not sequestered by circulating binding proteins as efficiently as full-length IGF-1, enabling more immediate receptor access.
The compound's shorter half-life (approximately 30 minutes) and site-specific administration protocol position it as a research tool for studying local rather than systemic IGF-1 signalling. Research protocols typically involve injection at or near target tissue sites (commonly trained muscle groups) to investigate localised anabolic pathway activation.
IGF-1 DES is distinguished from IGF-1 LR3 (which has an extended half-life and systemic reach) by its shorter duration of action and reduced systemic exposure profile. These different pharmacokinetic characteristics make them useful for different experimental questions in IGF-1 axis research.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, igf-1 des (truncated igf-1) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
IGF-1 DES (Truncated IGF-1) research is most relevant to protocols examining:
Site-specific anabolic signalling and satellite cell activation research
Localised muscle repair biology studies
IGF-1 binding protein interaction comparison studies
Researchers contrasting short-acting DES vs long-acting LR3 IGF-1 variants
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~30 minutes). Review data, confirm baseline recovery before any repeat protocol.
Truncated IGF-1 variant lacking N-terminal tripeptide; reduced IGFBP binding affinity in some tissues enables more immediate IGF-1R access and localised anabolic pathway activation (PI3K/Akt/mTOR, Ras/MAPK) with shorter systemic duration than IGF-1 LR3.
| Parameter | Value |
|---|---|
| Dose range | 30–150 mcg/day (site-specific) |
| Schedule | Daily, post-workout (with carbohydrate proximate) |
| Route | Subcutaneous (site-specific) |
| Half-life | ~30 minutes |
must dose with carbohydrates nearby (dose-dependent)
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.